Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension

Journal of Hypertension

Volumn 17, Issue 7, 1999, Pages 1033-1039

  Puig, Juan G ^a,c   Mateos, Felicitas ^a   Buño, Antonio ^a   Ortega, Rafael ^b   Rodriguez, Felipe ^b   Dal Ré, Rafael ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b GLAXOSMITHKLINE   (United Kingdom)

^c NONE   (Spain)

Author keywords

Blood pressure; Eprosartan; Losartan; Uric acid

Indexed keywords

ANGIOTENSIN II ANTAGONIST; CREATININE; EPROSARTAN; LOSARTAN; URATE; URIC ACID;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; BORDERLINE HYPERTENSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL;

EID: 0032997748     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199917070-00021     Document Type: Article

References (36)

1. 1 Breckenridge A. Hypertension and hyperuricemia. Lancet 1966; i:15-18.
2. 2 Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med 1966; 275:457-464.
3. 3 Kahn HA, Medalie JH, Noufeld HN, Riss E, Goldbourt U. The incidence of hypertension and associated factors. The Israeli Ischemic Heart Disease Study. Am Heart J 1972; 84:171-182.
4. 4 Mikkelsen WM, Dodge HJ, Valkenburg H. The distribution of serum uric acid values in a population unselected as to gout or hyperuricemia. Am J Med 1965; 39:242-251.
5. 5 Jacobs DR, Berustein WH. Serum uric acid: its association with other risk factors and mortality in myocardial infarction. J Chron Dis 1976; 29:557-570.
6. 6 Ramsay LE. Hyperuricaemia in hypertension: role of alcohol. BMJ 1979; i:653-654.
7. 7 Messerli FH, Frohlich DE, Dreslinnski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93:817-821.
8. 8 Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia. Am J Med 1967; 42:27-37.
9. 9 The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2446.
10. 10 Scott JT, Higgens CS. Diuretic induced gout: a multifactorial condition. Ann Rheum Dis 1992; 51:259-261.
11. 11 Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42:333-335.
12. 12 Burnier M, Rutschmann B, Nussberger J, Versaggi J, Shahinfar S, Waeber B, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993; 22:339-347.
13. 13 Burnier M, Pechère-Bertschi A, Nussberger J, Waeber B, Brunner HR. Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems. Am J Kidney Dis 1995; 26:108-115.
14. 14 Tsunoda K, Abe K, Hagino T, Omata K, Misawa S, Imai Y, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993; 6:28-32.
15. 15 Fauvel JP, Velon S, Berra N, Pozet N, Madonna O, Zech P, et al. Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol 1996; 28:259-263.
16. 16 Price DA, De'Oliveira JM, Fisher NDL, Hollenberg NK. Renal haemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension 1997; 30:240-246.
17. 17 Boike S. Ilson B, Audet P, Freed M, Everitt D, Brown L, et al. The angiotensin II receptor antagonist SK&F 108566 does not increase uric acid (UA) excretion in healthy men [Abstract]. J Am Soc Nephrol 1993; 4:530.
18. 18 Becker MA, Roessler BJ. Hyperuricemia and gout. In: Scriver CR, Beaudet AL, Sly WS, Valle D (editors): The metabolic and molecular bases of inherited disease. New York: McGraw-Hill Inc; 1995, pp. 1655-1677.
19. 19 Brunner HR, Delacrétaz E, Nussberger J, Burnier M, Waeber B. Angiotensin II antagonists DuP 753 and TCV 116. J Hypertens 1994; 12(suppl 9);S29-S34.
20. 20 Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346:1403-1407.
21. 21 Gardner M, Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. BMJ 1986; 292:746-750.
22. 22 Mateos FA. Puig JG, Fox IH. Hereditary xanthinuria: evidence for enhanced hypoxanthine salvage. J Clin Invest 1987; 79:847-852.
23. 23 Puig JG, Miranda ME, Mateos FA, Picazo ML, Jiménez ML, Calvin TS, et al. Hereditary nephropathy associated with hyperuricemia and gout. Arch Intern Med 1993; 153:357-365.
24. 24 Puig JG, Mateos FA, Miranda ME, Torres RJ, de Miguel E, Pèrez de Ayala C, et al. Purine metabolism in women with primary gout. Am J Med 1994; 97:332-338.
25. 25 Ruilope LM, Simpson RL, Ton J, Arcuri KE, Goldberrg AI, Sweet CS. Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Pressure 1996; 5:32-40.
26. 26 Wortmann RL, Ridolfo AS, Lightfoot RW, Fox IH. Antihyperuricemic properties of amflutizole in gout. J Rheumatol 1985; 12:540-543.
27. 27 Gutman AB, Yü T-F. Protracted uricosuric therapy in tophaceous gout. Lancet 1975; ii:1258-1259.
28. 28 Sweet CS, Bradstreet DC, Berman RS, Jallard N, Saenz A, Weidler DJ. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994; 7:1035-1040.
29. 29 Roch-Ramel F, Diezi J. Renal transport of organic ions and uric acid. In: Schrier RW, Gottschalk CW (editors): Diseases of the kidney, 6th Edn, Vol. I. Boston: Little Brown & Co.; 1996, pp. 231-249.
30. 30 Edwards RM, Trizna W, Stack E, Weinstock J. Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes. J Pharmacol Exp Ther 1996; 276:125-129.
31. 31 Diamond HS. Uricosuric drugs. Handbook Exp Pharmacol 1978; 51: 459-484.
32. 32 Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, Brouard R, et al. Short-term and sustained renal effects of angiotensin II blockade in healthy subjects. Hypertension 1995; 25(part 1):602-609.
33. 33 Van den Meiracker AH, Admiraal PJJ, Janssen JA, et al. Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. Hypertension 1995;25:22-29.
34. 34 Bernhart CA, Perreaut PM, Ferrari BP, Muneaux YA, Assens J-LA, Clement J, et al. A new series of imidazolones: highly specific and potent nonpeptide AT sub(1) angiotensin II receptor antagonists. J Med Chem 1993; 36:3371-3380.
35. 35 Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron 1991; 59:364-368.
36. 36 Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 1996; 49:1787-1790.